Recent Finacing
Recent Raise
EydisBio develops TAK1 kinase inhibitors for autoimmune and inflammatory diseases, advancing analog optimization and GLP preclinical studies toward an IND for treating systemic sclerosis and SSc-ILD.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor